Company News

June 22, 2023

The return of Altria’s equity stake and termination of underlying agreements affords us full strategic freedom – we are no longer limited by the terms of those agreements to pursue other strategic opportunities and partnerships. We are free to take advantage of a range of options to maximize the value of our company while we continue to advance our leading product technology and innovation pipeline.

As part of our ongoing strategic review, we remain guided by our mission: transition the world’s billion adult smokers away from combustible cigarettes, eliminate their use, and combat underage usage of our products. Toward that end, we continue to take a methodical approach to resolve issues from the company’s past, engage constructively with stakeholders, and lead with innovation and science.

And it’s our innovation and science that drive our path forward and harm-reduction opportunity. While our appeal of FDA’s now-stayed MDO remains pending, we remain as confident in our science and evidence to support the continued marketing of JUUL products. We also continue to pursue future applications for new products to accelerate our mission and progress for the adult smoker, public health, and an end to combustible cigarettes.